MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
16.32
-0.44 (-2.63%)
At close: Sep 5, 2025, 4:00 PM
16.29
-0.03 (-0.18%)
After-hours: Sep 5, 2025, 4:41 PM EDT
MediWound Revenue
MediWound had revenue of $5.71M in the quarter ending June 30, 2025, with 12.74% growth. This brings the company's revenue in the last twelve months to $19.86M, down -1.41% year-over-year. In the year 2024, MediWound had annual revenue of $20.22M with 8.22% growth.
Revenue (ttm)
$19.86M
Revenue Growth
-1.41%
P/S Ratio
8.81
Revenue / Employee
$178,901
Employees
111
Market Cap
177.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MDWD News
- 4 days ago - MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress - GlobeNewsWire
- 4 days ago - MediWound Is A Buy Opportunity On The Dip - Seeking Alpha
- 17 days ago - MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 23 days ago - MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 24 days ago - MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers - GlobeNewsWire
- 4 weeks ago - MediWound to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript - Seeking Alpha